In addition to the autologous therapy, the alloSHRINK study investigated the allogeneic NKG2D CAR T-cell construct named CYAD-101 in combination with chemotherapy in metastatic colorectal cancer and showed a manageable safety profile and early clinical activity [75]. Here, KLRK1 is linked to metastatic colorectal cancer.